
Keywords: cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab; anti-CTLA4; anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1; anti-programmed cell death protein 1; anti-PDL1; anti-programmed death-ligand 1; AUC; area un